“It is a privilege to help bring the advances of personalized medicine to our patients and physicians worldwide. At Genomic Health, our scientists have collaborated with many of the most talented research groups in the world and I take great pride in being able to provide our patients, physicians, and insurance providers with the data and confidence they require to make critical, rational, and individualized treatment decisions.”
Committed to expanding patient access to Genomic Health’s tests, Jim currently serves as Chief Commercial Officer, and oversees US and International sales, marketing, reimbursement and customer support efforts. Most recently, Jim led the US marketing teams and portfolio planning for both near and long-term strategy. From 2009 through 2012, Jim drove the expansion of Genomic Health’s international business efforts in Geneva, Switzerland. In Geneva, Jim and team focused on collaborating with early adopting physicians in Canada, Ireland, Spain, Germany, and the UK, to support broader Oncotype DX reimbursement and patient access. These pioneering efforts, coupled with the experience that physicians across Europe had with the test, led to the inclusion of the Oncotype DX Breast Cancer Assay in the prestigious St. Gallen guidelines in 2011. Prior to leading the marketing teams at Genomic Health, Jim worked in the managed care setting and led Genomic Health’s Western U.S. sales efforts from 2005 through 2008. Before joining Genomic Health, Jim was Vice President of Cerus Corporation, a biomedical products company, where he directed marketing and medical affairs. Prior to this appointment, Mr. Vaughn held a number of positions in sales, sales management, and marketing, including the role as Senior Director of Global Oncology Franchise with Celebrex. Jim holds a Bachelor of Science degree in Pharmacy from Creighton University and an MBA from Northwestern University, Kellogg School of Business.